Navigate back to the homepage

COVIND — COVID 19 Individual Patient Data Consortium

Mostapha Benhenda
May 11th, 2020 · 2 min read

COVIND is a global registry of COVID-19 individual patient data. It accelerates pooling of high-quality patient data, while ensuring the strongest data protection standards.


A lot of clinical studies about COVID-19 are being published. However, most of them only release aggregated cohort data, without individual patient data. This makes secondary data analysis much more difficult. For example:

Clinical outcomes heavily depend on individual patient characteristics, which are lost by data aggregation.

For example, these 2 datasets with 2 patients are the same at the aggregated level, but they can still give different clinical outcomes:

On the other hand, COVIND database will comprise individual pseudonymized data. It will look like:

We also plan to add CT scans and other relevant information from electronic health records.

COVIND use-cases

With COVIND database, we plan to better evaluate therapies, such as:

  • Chloroquine
  • Azithromycin
  • Tocilizumab
  • Artemisia
  • Remdesivir…

We also plan to evaluate interventions such as:

  • Extra-Corporeal Membrane Oxygenation
  • Invasive Ventilation
  • Helmet Ventilation
  • High-Flow Nasal Cannula…

These projects will rely on the latest AI and machine learning technologies, as outlined in this article.

COVIND is patient-centered

In addition to their revocable and explicit consent, patients will be able to monitor the impact of their data donation on scientific findings, on a platform suitable for a general audience. This will help them understand research purposes. With this pandemic, appetite for research in infectious diseases is growing among the public. Moreover, this platform will facilitate patient long-term follow-up.

COVIND is GDPR-compliant

Data protection is guaranteed by the European GDPR, one of the strictest privacy regulations in the world. We can also comply with other local regulations upon request.

Membership benefits for hospitals

  • Accelerate research by accessing the consortium network
  • Upgrade hospital IT infrastructure, with state-of-the-art technologies in artificial intelligence and big data

To join the consortium as a doctor, sponsor or partner, drop a message to Mostapha Benhenda (, or fill the form.


  • Assiut, Egypt

Aliae Hussein, MD
Professor, Department of Chest Diseases, Faculty of Medicine, Assiut University

  • Brescia, Italy

Elena Torri, MD
BresciaMEd - Ambulatorio Medico ecografie e visite urgenza

  • Cambridge, Massachusetts, United States of America

Christopher Barrett, MD
Affiliate MIT Researcher
Beth Israel Deaconess Medical Center
Harvard Medical School

Michael B. Yaffe, MD
Director of the Yaffe Lab
Professor of Biology and Biological Engineering, Koch Institute for Integrative Cancer Research, Center for Precision Cancer Medicine at MIT
Beth Israel Deaconess Medical Center

  • Cremona and Trieste, Italy

Daniele Generali, MD
Direttore di U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale, Azienda Socio-Sanitaria Territoriale di Cremona
Professore Associato in Oncologia Medica
Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute, Università degli Studi di Trieste

  • Denver, Colorado, United States of America

Ernest E. Moore, MD
Ernest E. Moore Shock Trauma Center at Denver Health

Hunter Moore, MD
Division of Transplant Surgery, Department of Surgery, University of Colorado

  • Lahore, Pakistan

Ahmad Imran, MBBS
Shaikh Zayed Hospital

Qurrat ul Ain Iqbal, MBBS
Shaikh Zayed Hospital

  • London, United Kingdom

Emmanuel Ako, MD
Department of Cardiology at Chelsea and Westminster NHS hospital

  • Moscow, Russia

Altana Mikhakhanova, MD
NPO Petrovax Pharm LLC, a full-cycle biopharmaceutical company

  • Paris, France

Mostapha Benhenda, PhD
Data scientist, Melwy

  • Rome, Italy

Danilo Buonsenso, MD
U.O.C. di Pediatria, Fondazione Policlinico Universitario “A. Gemelli”

  • Tehran, Iran

Seyed Sina Naghibi Irvani, MD, MPH, MBA
Shahid Beheshti University of Medical Sciences

  • Tübingen, Germany

Diane Egger-Adam, MD, Project Manager
Institute of Tropical Medicine, University of Tübingen

More articles from Melwy

Coronavirus therapeutics - Real World Evidence with AI can deliver results faster

Coronavirus pandemic is all the rage around the world, and so is the race for cures, and for their evaluation.

April 21st, 2020 · 3 min read

60,000 Euros Immuno-Oncology AI4Curie challenge - remarks and questions

The Curie Institute, a cancer research center in Paris, launched the AI4Curie challenge, about AI for immunotherapy.

March 8th, 2020 · 3 min read
© 2019–2021 Melwy
Link to $ to $ to $ to $ to $